# Preeclampsia Postpartum Antihypertensive Treatment

Study · id `cardio:ct-nct04298034` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04298034](<https://clinicaltrials.gov/study/NCT04298034>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04298034

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 300 participants.

## Technical summary

Registry record NCT04298034. Randomized; single masking; primary purpose treatment. Start 2020-07-17 (actual); primary completion 2025-06-30 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 300 participants (planned count; ClinicalTrials.gov record NCT04298034, source copy `cardio:ctgov-nct04298034-2026-07-20`, retrieved 2026-10-26)
- Started: 2020-07-17 (actual) (ClinicalTrials.gov record NCT04298034, source copy `cardio:ctgov-nct04298034-2026-07-20`, retrieved 2026-10-26)
- Primary completion: 2025-06-30 (actual) (ClinicalTrials.gov record NCT04298034, source copy `cardio:ctgov-nct04298034-2026-07-20`, retrieved 2026-10-26)
- Completion: 2026-09-30 (anticipated) (ClinicalTrials.gov record NCT04298034, source copy `cardio:ctgov-nct04298034-2026-07-20`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT04298034, source copy `cardio:ctgov-nct04298034-2026-07-20`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04298034-2026-07-20`, retrieved 2026-10-26)

## The registry's words

- Brief title: Preeclampsia Postpartum Antihypertensive Treatment
- Acronym: P-PAT
- Condition: Preeclampsia
- Condition: Hypertension in Pregnancy
- Intervention (Drug): Labetalol, Nifedipine
- Lead sponsor: Medical College of Wisconsin
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Medical College of Wisconsin (`cardio:org-medical-college-of-wisconsin`)

## Provenance

Content hash: f058d39cd73737c0769e291cdba0a05ae34a56cbac1df3453e72c9af05b5d050
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
